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Objective: There is increasing evidence that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) reduce
cardiovascular and cerebrovascular events through anti-inflammatory, plaque stabilization, and neuroprotective effects
independent of lipid lowering. This study was designed to investigate whether statin use reduces the incidence of
perioperative stroke and mortality among patients undergoing carotid endarterectomy (CEA).
Methods: All patients undergoing CEA from 1994 to 2004 at a large academic medical center were retrospectively
reviewed. The independent association of statin use and perioperative morbidity was assessed via multivariate logistic
regression analysis.
Results: CEA was performed by 13 surgeons on 1566 patients (987 men and 579 women; mean age, 72  10 years),
including 1440 (92%) isolated and 126 (8%) combined CEA/coronary artery bypass grafting procedures. The indication
for CEA was symptomatic disease in 660 (42%) cases. Six hundred fifty-seven (42%) patients received a statin medication
for at least 1 week before surgery. Statin use was associated with a reduction in perioperative strokes (1.2% vs 4.5%; P <
.01), transient ischemic attacks (1.5% vs 3.6%; P < .01), all-cause mortality (0.3% vs 2.1%; P < .01), and median
(interquartile range) length of hospitalization (2 days [2-5 days] vs 3 days [2-7 days]; P < .05). Adjusting for all
demographics and comorbidities in multivariate analysis, statin use independently reduced the odds of stroke threefold
(odds ratio [95% confidence interval], 0.35 [0.15-0.85]; P < .05) and death fivefold (odds ratio [95% confidence
interval], 0.20 [0.04-0.99]; P < .05).
Conclusions: These data suggest that perioperative statin use may reduce the incidence of cerebrovascular events and
mortality among patients undergoing CEA. (J Vasc Surg 2005;42:829-836.)
Carotid stenosis is established as the leading cause of
stroke-related morbidity, which accounts for the foremost
cause of adult disability, the second most significant cause
of dementia, and the third most common cause of death in
Western nations.1,2 Carotid endarterectomy (CEA) re-
mains the “gold standard” treatment for asymptomatic and
symptomatic carotid stenosis in the prevention of cerebro-
vascular events.3,4 Over the last two decades, there has been
dramatic improvement in postoperative outcomes after
CEA.5 Despite the documented safety of CEA, carotid
angioplasty and stenting has been introduced as a mini-
mally invasive alternative treatment of carotid artery disease
and is challenging the accepted role of the conventional
surgical treatment of this patient population.6 Therefore,
continued reduction in CEA-related morbidity is necessary
to maintain CEA as the gold standard therapy for occlusive
carotid disease.
CEA-related strokes may result from dislodged em-
bolic plaque during carotid manipulation, watershed isch-
emia during carotid cross clamping, or postoperative
thrombosis and embolism.7,8 Reduction of all phenomena
may be necessary to achieve a reduction in perioperative
strokes. Recently, 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors (statins) have been shown to stabilize
arterial plaques, improve cerebrovascular autoregulation
and blood flow, and serve as neuroprotectants in both in
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vitro and in vivo experimental studies.9-12 Statins have also
been shown to be effective agents in the primary and
secondary prevention of stroke in patients with known
vascular disease.13-16 The purpose of this study was to
examine the role of statin therapy in perioperative out-
comes after CEA, including cerebrovascular events, myo-
cardial infarction (MI), mortality, cranial nerve injury, and
length of hospital stay.
METHODS
All patients who underwent CEA between 1994 and
2004 at the Johns Hopkins Hospital and the Johns Hop-
kins Bayview Medical Center were identified. Patient de-
mographics, clinical presentation, radiologic records, oper-
ative notes, and clinical outcomes were retrospectively
obtained and available for review in all cases. All clinical,
operative, and outcome variables were defined and docu-
mented by the surgeon at the time of operation. No variables
or outcomes were retrospectively defined. Patients were clas-
sified as smokers if they were active smokers at the time of
operation. Symptomatic disease was documented when pa-
tients experienced transient ischemic attacks (TIAs) or stroke
documented by a neurologist as attributed to carotid artery
stenosis. All comorbidities were recorded from the admis-
sion history and physical and the discharge summary.
Plaques were defined as ulcerative if documented on the
carotid imaging report or clearly noted in the operative
report. Patients were classified as receiving shunts or
patches if operative notes documented the use of an intralu-
minal shunt or carotid patch, respectively. Chronic renal
insufficiency was defined as a serum creatinine level greater
than 1.4 mg/dL on hospital admission in the absence of
acute renal pathology. Patients using 3-hydroxy-3-methyl-
glutaryl coenzyme A reductase inhibitors for at least 1 week
before surgery were classified as statin users. Patients were
determined to be receiving a statin if they were already
taking the medication at the time of their preoperative
evaluation, which occurred at least 1 week before surgery.
For the subset of patients who were already admitted to the
hospital and underwent CEA surgery without an outpa-
tient evaluation, statin users were defined by their admis-
sion medication list as reported by their admitting service
before surgery. The degree of carotid stenosis was defined
by two concordant studies, including duplex ultrasonogra-
phy, cerebral angiography, and magnetic resonance an-
giography. For the purposes of this study, percentage ste-
nosis was defined as the average of the two imaging
modalities. New-onset postoperative neurologic deficits
lasting less than 24 hours were defined as TIAs. Deficits
lasting longer than 24 hours were classified as postoperative
stroke. All complications occurring within 30 days of CEA
(MI, pulmonary embolism, cranial nerve deficits, and neck
hematoma) were considered perioperative morbidities. In
the setting of perioperative stroke, a neurologist was rou-
tinely consulted and documented the presence of stroke.
MI was defined by the vascular surgeon or intensive care
physician at the time of the event and was documented
when there was clinical evidence of either unstable angina
or an acute change in cardiac output in the setting of
electrocardiogram changes and increased cardiac enzymes.
For intercohort comparison, continuous data were
compared via two-way analysis of variance for continuous
data and Mann-Whitney U test for categorical data. Per-
centages were compared via 2 tests. The univariate associ-
ation of statin use and perioperative stroke, MI, and death
was assessed via logistic regression analysis (StatView; SAS
Institute, Cary, NC). The independent association of statin
use with perioperative stroke, MI, and death was assessed
via multivariate logistic regression analysis (StatView). All
covariables associated with stroke or death (P value .10 in
univariate analysis) were included in the multivariate logis-
tic regression model (StatView).
RESULTS
Patient population. CEA was performed on 1566
patients at the Johns Hopkins Hospital or Johns Hopkins
Bayview Medical Center between 1994 and 2004, includ-
ing 126 (8%) patients who underwent a combined CEA/
coronary artery bypass grafting (CABG) procedure. The
operations were performed by 13 attending surgeons, in-
cluding 10 vascular surgeons and 3 neurosurgeons. There
were 987 (63%) male and 579 (37%) female patients, with
a mean age of 72.2  9.9 years; this population included
1408 (90%) white, 142 (9%) black, 14 (1%) Asian, and 2
(0.1%) Hispanic individuals. Comorbidities included hy-
pertension in 1247 (80%), hyperlipidemia in 787 (50%),
coronary artery disease in 765 (49%), diabetes mellitus in
407 (26%), smoking in 372 (24%), history of MI in 296
(17%), history of CABG in 268 (17%), history of atrial
fibrillation in 153 (10%), congestive heart failure in 128
(8%), and chronic renal insufficiency in 87 (6%) patients. In
every case, the operated stenosis was greater than 50%, and
it was greater than 70% in 94.8% and greater than 80% in
83.8% of cases. An ulcerated plaque was noted in 215 (19%)
cases.
The indication for operation was symptomatic disease
in 660 (42%) patients, including a history of stroke in 226
(14%), TIAs in 434 (28%), and asymptomatic stenoses in
906 (58%) cases. The technical details of the operation
varied with surgeon preference. Intraluminal shunts were
used in 1195 (76.3%) cases, and patch closure was per-
formed in 860 (54.9%) cases. The operation was performed
with patients under general anesthesia in 1447 (92.4%) and
under cervical block in 119 (7.6%) cases.
At the time of operation, 657 (42%) patients were
taking a 3-hydroxy-3-methylglutaryl coenzyme A reduc-
tase inhibitor (statin) drug. The agents included atorvasta-
tin in 332 patients (mean dose, 20  10 mg/d), simvasta-
tin in 189 patients (mean dose, 20 10mg/d), pravastatin
in 91 patients (mean dose, 30 20mg/d), lovastatin in 32
patients (mean dose, 30 10 mg/d), and fluvastatin in 13
patients (mean dose, 3010mg/d). Patients taking statins
were significantly younger, were more often male, and
more frequently had hyperlipidemia, coronary artery dis-
ease, hypertension, and a history of smoking. Chronic renal
insufficiency, symptomatic carotid disease, and the use of a
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carotid patch were more frequent in patients not taking
statins (Table I).
Perioperative morbidity. There were 21 (1.3%)
perioperative deaths and 49 (3.1%) perioperative strokes.
MIs occurred in 25 (1.6%), cranial nerve deficits in 66
(2.3%), and neck hematomas in 36 (2.3%) cases. The
mean length of stay was 3 days. Univariate analysis
revealed that statin use was associated with a reduction in
perioperative strokes (1.2% vs 4.5%; P  .01), perioper-
ative TIAs (1.5% vs 3.6%; P  .01), mortality (0.3% vs
2.1%; P  .01), and the median (interquartile range)
length of hospitalization (2 days [2-5 days] vs 3 days
[2-7 days]; P  .05; Table II).
In multivariate analysis of perioperative stroke, ad-
justing for all comorbidities that were associated with
stroke in univariate analysis (symptomatic carotid dis-
ease, chronic atrial fibrillation, hyperlipidemia, intralu-
minal shunt and patch grafting use, and combined CEA/
CABG), statin use remained independently associated
with a threefold reduction in the odds of perioperative
stroke (odds ratio [95% confidence interval], 0.29 [0.14-
0.61]; P  .05; Table III). This decrease in perioperative
stroke rate observed with statin use persisted regardless
of the year of surgery (Fig 1). Symptomatic carotid
stenosis and combined CEA/CABG were associated
with an increased risk of stroke (Table III).
In multivariate analysis of perioperative mortality, ad-
justing for all comorbidities that were associated with mor-
tality in univariate analysis (percentage carotid stenosis,
hypertension, chronic atrial fibrillation, coronary artery dis-
ease, congestive heart failure, chronic renal insufficiency,
use of -blockers, and combined CEA/CABG), statin use
remained independently associated with a sevenfold reduc-
tion in the odds of perioperative death (odds ratio [95%
confidence interval], 0.14 [0.03-0.62]; P  .05; Table IV).
-Blocker use was also independently associated with a
decreased risk of perioperative mortality, whereas chronic
atrial fibrillation, chronic renal insufficiency, and combined
CEA/CABG were associated with an increased risk of
mortality (Table IV).
DISCUSSION
CEA has proven to be the treatment of choice for
symptomatic and asymptomatic carotid artery stenosis and
is the most frequently performed noncardiac vascular pro-
cedure. However, postoperative complications of CEA,
including stroke and mortality, remain significant risks as-
sociated with this procedure, with pooled estimates ranging
as high as 4% to 8%.3,4 Our data suggest that perioperative
statin therapy significantly reduces the risks of these adverse
outcomes in patients undergoing CEA. Statin use was
associated with a lower 30-day rate of stroke, TIA, and
all-cause mortality. These results were supported by multi-
variate regression analysis, which adjusted for potential
cofounders and found that statin therapy was indepen-
dently associated with a threefold and fivefold reduction in
the risk for stroke and mortality, respectively.
There is a lot of speculation regarding potential
mechanisms to account for statins’ reduction in cerebro-
vascular events. Statins effectively reduce plasma concen-
trations of low-density-lipoprotein cholesterol, which
has long been an established risk factor in the pathogen-
esis of coronary heart disease.17 However, there has been
Table I. Patient demographics, clinical presentation,
radiologic characteristics, and operative variables in the
statin and nonstatin treatment groups
Variable
Statin
(n  909)
Nonstatin
(n  657) P value
Age (y) 70  10 74  10 .001*
Male 436 (66%) 551 (61%) .020†
Left side 346 (53%) 425 (47%) .021†
% Stenosis 84%  10% 86%  10% .001
Symptomatic disease 228 (35%) 432 (47%) .001†
TIA presentation 156 (24%) 278 (31%) .003†
Stroke presentation 72 (11%) 154 (17%) .001†
Caucasian 589 (90%) 818 (90%) .567†
DM 186 (28%) 221 (24%) .075†
HTN 561 (85%) 686 (75%) .001†
Atrial fibrillation 29 (4%) 44 (4%) .693†
CHF 56 (9%) 72 (8%) .667†
Hyperlipidemia 533 (81%) 254 (28%) .001†
CAD 376 (57%) 389 (43%) .001†
History of MI 148 (23%) 148 (16%) .002†
Smoker 196 (30%) 176 (19%) .001†
CRI 24 (4%) 63 (7%) .005†
Contralateral stenosis 137 (21%) 150 (17%) .028†
Ulceration 78 (12%) 137 (15%) .695†
Local anesthesia 45 (6.8%) 74 (8.1%) .341†
Selective shunting 78 (12%) 91 (10%) .241†
Shunt 501 (76%) 694 (76%) .966†
Surgical frequency
(n/3 mo) 11  6 10  6 .114*
Graft 312 (47%) 55 (60%) .001†
CABG/CEA 60 (9%) 66 (7%) .179†
Data are n (%) unless otherwise noted.
TIA, Transient ischemic attack;DM, diabetes mellitus;HTN, hypertension;
CHF, congestive heart failure;CAD, coronary artery disease;MI,myocardial
infarction; CRI, chronic renal insufficiency; CABG, coronary artery bypass
grafting; CEA, carotid endarterectomy.
Statin users more frequently had left-sided disease, hypertension, hyperlip-
idemia, CAD, a history of MI, a history of smoking, and contralateral
stenosis; were younger; and were more frequently male. Statin users less
frequently had symptomatic disease, CRI, and carotid patching (graft).
*Two-way analysis of variance.
†Chi-square test.
Table II. Outcome comparison of statin and nonstatin
treatment groups after carotid endarterectomy
Outcome
Statin
(n  657)
Nonstatin
(n  909) P value
Stroke 8 (1.2%) 41 (4.5%) .002
Cranial nerve deficit 29 (4.4%) 38 (4.1%) .823
MI 8 (1.2%) 19 (2.1%) .191
Mortality 2 (0.3%) 19 (2.1%) .002
Data are n (%) unless otherwise noted.
MI, Myocardial infarction.
Patients receiving statin therapy at the time of carotid endarterectomy
experienced a lower rate of stroke and mortality.
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debate as to the extent that hyperlipidemia contributes
to cerebrovascular disease and the risk of stroke. Epide-
miologic and large observational studies have not con-
sistently demonstrated an association between choles-
terol levels and all causes of stroke.18 Nevertheless, the
results of numerous clinical trials over the past decade
have found that statin therapy reduces the risk of cere-
brovascular events in high-risk medical patients.13-16 A
recent meta-analysis of all randomized trials testing sta-
tin drugs including more than 90,000 patients found a
21% risk reduction for stroke, which was closely corre-
lated with reductions in levels of low-density-lipoprotein
cholesterol.16 These findings are supported by several
reports showing that statin therapy slows the progression of
carotid atherosclerosis and reduces carotid intima-media
thickness.19,20 Moreover, the large randomized Heart Pro-
tection Study trial, comprising more than 20,000 patients
with occlusive arterial disease, showed that statin therapy
significantly reduced the number of patients who had
strokes or TIAs and subsequently required CEA or angio-
plasty.15 Still, It is interesting to note that when 3200
patients from this large study with known pre-existing
cerebrovascular disease were evaluated by subgroup analy-
sis, statin therapy was not found to be associated with a
reduction in the secondary stroke rate. It is difficult to
compare these results with those of the present study, given
the differences in the demographic and perioperative risk
profile of our patients. Furthermore, the risks for cerebro-
vascular disease and adverse neurologic sequelae differ be-
tween medical and surgical patients.
It has come to light through numerous in vitro and in
vivo studies over recent years that statins have other bene-
ficial effects that are independent of lipid lowering. These
Table III. Univariate and multivariate association of clinical, radiographic, and surgical variables with perioperative
stroke after carotid endarterectomy
Univariate Multivariate
Variable Odds ratio (95% CI) P value Odds ratio (95% CI) P value
Age 0.99 (0.97-1.02) .692
Male 1.14 (0.63-2.07) .667
Caucasian 1.17 (0.42-3.29) .767
Right CEA 0.62 (0.35-1.10) .105
Symptomatic carotid stenosis 1.77 (1.03-3.12) .048 2.14 (1.15-4.03) .017
% Stenosis 1.02 (0.99-1.05) .231
Ulcerative plaque 0.85 (0.36-2.02) .712
Contralateral carotid stenosis 0.72 (0.32-1.62) .424
Diabetes 1.63 (0.90-2.93) .105
Hypertension 1.16 (0.56-2.43) .681
Chronic atrial fibrillation 2.36 (0.91-6.13) .078 2.51 (0.96-6.93) .067
Hyperlipidemia 0.43 (0.23-0.79) .006 0.58 (0.29-1.16) .123
Coronary artery disease 1.23 (0.70-2.17) .468
Congestive heart failure 1.55 (0.65-3.72) .323
Active smoker 0.96 (0.49-1.89) .898
Chronic renal insufficiency 1.47 (0.52-4.21) .464
Statin use 0.29 (0.14-0.61) .001 0.41 (0.18-0.93) .033
ACE inhibitor use 1.57 (0.86-2.84) .140
Calcium channel blocker use 1.06 (0.56-1.98) .867
-Blocker use 0.91 (0.51-1.62) .751
Vascular surgeon 2.05 (0.49-8.55) .323
Local anesthesia 1.06 (0.37-2.99) .919
Intraluminal shunt 2.83 (1.11-7.17) .029 2.10 (0.75-5.88) .157
Carotid patch 1.94 (1.05-3.58) .034 1.32 (0.66-2.65) .424
Combined CEA/CABG 3.87 (1.97-7.61) .001 5.54 (2.58-11.7) .001
CI, Confidence interval; CEA, carotid endarterectomy; ACE, angiotensin-converting enzyme; CABG, coronary artery bypass grafting.
Statin use was independently associated with a lower risk of perioperative stroke. Symptomatic carotid stenosis and combinedCEA/CABGwere associated with
an increased risk of stroke.
Fig 1. Incidence of postoperative stroke after carotid endarterec-
tomy as a function of statin vs no statin use over time. The
postoperative stroke rate remained lower in patients receiving
statins, regardless of the year of operation.
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non–lipid-mediated, or pleiotropic functions of statins in-
clude diverse cellular effects, including increased endothe-
lial nitric oxide synthase (eNOS) expression; reduced pro-
duction of endothelin 1 and reactive oxygen species;
reduction in inflammatory molecules, including C-reactive
protein, cytokines, chemokines, adhesion molecules, and
C-reactive protein; reduction of intravascular thrombosis;
and regulation of vascular smooth muscle cell migration
and proliferation.21-26 The clinical benefits of these pleiotro-
pic effects during the CEA perioperative period may derive
through several means. Statins’ upregulation of eNOS can
help control vasomotor tone, inhibit leukocyte and platelet
adhesion, and maintain a thromboresistant interface between
the bloodstream and the vessel wall.10,11,27 These effects on
the vascular endothelium might consequently protect the
brain during the operation by improving collateral blood
flow and enhancing cerebral arterial vasodilation during
states of compromised blood flow, as well as by preventing
carotid thrombosis and embolism during the postoperative
period. This is supported by several animal models of
ischemic stroke, which showed that statin therapy reduced
infarct size by up to 46% through upregulating eNOS and
improving cerebral blood flow.27,28 Another potential
source of cerebral protection attributable to statin
pleiotropy during the CEA perioperative period is the
stabilization of carotid atheromatous plaques. Many in
vitro and in vivo data have shown that statin therapy
suppresses numerous inflammatory processes that de-
grade the extracellular matrix, promote thrombosis, and
lead to plaque disruption.8-10,12,21-24 Statin therapy
taken during the preoperative period may therefore stabi-
lize carotid plaques that would otherwise be disrupted,
embolize, and lead to a perioperative stroke. Several recent
studies support this conclusion by showing that carotid
plaques taken from patients after CEA had significantly
lower levels of matrix metalloproteinases 1, 2, and 9 and
interleukin 6, along with fewer macrophages and higher
collagen contents, if they were taking a preoperative statin
medication.29,30
A host of clinical studies have been published during
the past several years that support the use of statin therapy
to reduce complications after vascular surgery. In two sep-
arate retrospective studies, perioperative statin therapy was
associated with a significant reduction in the 30-day and
1-year mortality after CABG surgery.31,32 Statin use was
also independently associated with a reduced risk of 30-day
and 6-month mortality in patients undergoing percutane-
ous coronary interventions.33 In patients undergoing elec-
tive abdominal aortic aneurysm (AAA) repair, Kertai et al34
found that statin therapy was associated with a significantly
lower incidence of perioperative mortality. Abbruzzese et al35
found that statin therapy was associated with improved
secondary graft patency in patients undergoing autogenous
infrainguinal bypass procedures but that it did not affect
Table IV. Univariate and multivariate association of clinical, radiographic, and surgical variables with perioperative
mortality after carotid endarterectomy
Univariate Multivariate
Variable Odds ratio (95% CI) P value Odds ratio (95% CI) P value
Age 1.01 (0.97-1.06) 0.647
Male 0.64 (0.27-1.51) .309
Caucasian 0.96 (0.22-4.11) .957
Right CEA 0.51 (0.20-1.27) .146
Symptomatic carotid stenosis 0.68 (0.27-1.69) .406
% Stenosis 1.07 (1.01-1.39) .021 1.06 (0.99-1.14) .097
Ulcerative plaque 0.02 (0.01-1.12) .972
Contralateral carotid stenosis 2.26 (0.91-5.65) .081
Diabetes 1.43 (0.57-3.59) .443
Hypertension 0.41 (0.17-0.99) .048 0.30 (0.16-1.18) .091
Chronic atrial fibrillation 5.02 (1.64-15.3) .004 3.88 (1.05-14.4) .042
Hyperlipidemia 0.62 (0.26-1.51) .293
Coronary artery disease 3.39 (1.24-9.30) .018 2.42 (0.71-8.27) .158
Congestive heart failure 3.60 (1.30-9.99) .014 1.83 (0.58-5.70) .299
Active smoker 1.06 (0.39-2.92) .906
Chronic renal insufficiency 7.11 (2.69-18.8) .001 5.41 (1.67-17.5) .005
Statin use 0.14 (0.03-0.62) .009 0.21 (0.05-0.96) .044
ACE inhibitor use 0.31 (0.72-1.34) .118
Calcium channel blocker use 0.63 (0.21-1.89) .414
-Blocker use 0.24 (0.07-0.83) .024 0.26 (0.07-0.98) .468
Vascular surgeon 1.69 (0.22-17.5) .610
Local anesthesia 1.28 (0.29-5.56) .541
Intraluminal shunt 0.98 (0.36-2.69) .968
Carotid patch 0.74 (0.31-1.79) .485
Combined CEA/CABG 11.1 (4.64-26.8) .001 14.7 (5.47-39.7) .001
CI, Confidence interval; CEA, carotid endarterectomy; ACE, angiotensin-converting enzyme; CABG, coronary artery bypass grafting.
Statin and -blocker use was independently associated with a lower risk of perioperative mortality. Chronic atrial fibrillation, chronic renal insufficiency, and
combined CEA/CABG were associated with an increased risk of mortality.
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perioperative mortality, major morbidity, or primary pa-
tency rates. Several other reports have recently been pub-
lished that have looked at perioperative statin therapy in
combined patients undergoing major noncardiac vascular
surgery, including both emergent and elective AAA repair,
lower extremity revascularization procedures, and CEA.
Two of these articles36,37 were reports of retrospective
case-control studies that found a significant reduction in
perioperative mortality and cardiovascular complications in
patients receiving statin therapy. Durazzo et al38 published
the only prospective trial in which 100 patients undergoing
major noncardiac surgery were randomized to atorvastatin
or placebo for 45 days, irrespective of their serum choles-
terol levels. Patients taking statins during the perioperative
period in this study were found to have a threefold decrease
in the rate of cardiovascular events (8.0% vs. 26%; P 
.031), including acute MI, ischemic stroke, and unstable
angina. However, because this study was heterogeneous
and contained a very limited number of CEA cases, no
conclusions could be made about statins’ ability to reduce
postoperative strokes after this specific procedure.
This is the first study to show a direct reduction in
cerebrovascular events after CEA. Patients in our statin
cohort had lower rates of stroke and mortality even though
they had more cardiovascular risk factors, including hyper-
tension, hyperlipidemia, coronary artery disease, a history
of MI, male sex, and smoking history. This increase in
cardiac morbidity among statin users might explain why no
significant differences were found in the incidence of MI
among cohorts, even though previous studies suggested that
statins reduce postoperative cardiac complications.36-38 Mul-
tivariate analysis confirmed that statin therapy was indepen-
dently associated with a reduction in the risk of stroke and
death, even after adjusting for all significant variables
found in our study, including symptomatic disease, com-
bined CEA/CABG, -blocker use, chronic atrial fibril-
lation, and chronic renal insufficiency. Nevertheless,
other confounders might have been present that were not
identified and adjusted for in our multivariate analysis. The
validity of our findings, like most published studies of
perioperative statin therapy to date, is limited by the retro-
spective design of the study. There was demographic het-
erogeneity between statin and nonstatin cohorts in this
study, and the duration of statin therapy before CEA was
unknown. Similarly, the difference in median length of
hospital stay between cohorts may have been influenced by
other factors that were not accounted for. Another main
limitation was that perioperative serum lipid levels were not
obtained and/or were not compared between statin and
nonstatin cohorts. Ultimately, large prospective ran-
domized trials will be needed to look at the influence of
statin therapy on the primary end points of stroke, MI,
and death after CEA, CABG, AAA repair, lower extrem-
ity bypass grafting, carotid stenting, or any other endo-
vascular revascularization procedure.
Moreover, it needs to be established how long patients
need to receive statin therapy before these procedures to
gain the drug’s benefit. Our study included patients in the
statin cohort if they had been taking the medication for at
least 1 week before surgery and continued taking it during
the 30-day postoperative period. However, other reports
have documented that patients need to receive the med-
ication for as long as 3 years to gain a stroke-reduction
benefit.15,39
Finally, are the potential benefits of statin therapy
enough to justify recommending that every patient be
given medication during the perioperative period, regard-
less of the serum cholesterol levels? A recent study looking
at the safety of perioperative statin use in high-risk patients
undergoing vascular surgery found no increased risk of
rhabdomyolysis or myopathy.40 It seems reasonable to
conclude that statin therapy might become a standard
agent to prescribe for most patients undergoing major
vascular procedures in the future.
CONCLUSION
The results of this retrospective study suggest that
the incidence of cerebrovascular events and mortality
in the first 30 days after CEA can be significantly reduced
with the perioperative use of statins. Prospective random-
ized trials will be needed to confirm the results of this study
and to determine the optimal use of statin therapy for the
surgical patient.
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DISCUSSION
Dr Richard Powell (Lebanon, NH). I think your results are
quite provocative. Could you postulate, since it seems unlikely that
the 30-day stroke and death rate was decreased because of the
anticholesterol effects of the statins, what are the other possible
mechanisms?
The second question I had is whether or not you saw any form
of dose-response relationship. Were the patients who were on
higher dose of statins likely to even gain a more beneficial effect
than patients on lower doses?
Dr Brooke. To answer your first question, there are several
effects that are associated with statin therapy, such as the upregu-
lation of nitric oxide production, which may help lower stroke
rates. Nitric oxide has numerous effects, including vasodilation and
control of vasomotor tone. There is also a known association
between nitric oxide upregulation and protecting the endothelial
surface during procedures, including preventing the attachment of
platelets and clotting factors. Thus, upregulation of nitric oxide
may be a very potent protective factor that is augmented by statins.
There is also a whole cascade of anti-inflammatory effects of
statin therapy that have been demonstrated. In vitro and in vivo
experiments have found that statins decrease levels of interleu-
kins, matrix metalloproteinases, and other by-products of in-
flammation. So there may be a potent plaque stabilization effect
that can be contributing to the reduction of stroke rates.
To answer your second question, we found that themean dose
for most patients in this study was at the lower end of the dose
spectrum. However, we didn’t perform a dose-effect correlation in
our analysis.
Dr Enrico Ascher (Brooklyn, NY). What were the causes of
stroke in the statin and nonstatin patients: were they similar?
Dr Brooke. Our analysis didn’t differentiate between the
potential etiologies of stroke.
Dr JohnChang (Roslyn, NY).When you do carotid surgery, do
you patch them?Do you close the arteriotomywith a primary closure?
Our study indicates that patch angioplasty using the proximal greater
saphenous vein has shown long-term beneficial effects in terms of
patency and recurrent stenosis.
My second question is to ask you whether or not you would
like to extend your study on a group that has milder disease, a
nonsurgical population, to treat them with statins for the long-
term study of beneficial effects of statin on the plaque to see
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whether or not there is evidence of regression, in comparison to the
control group that was not treated with statins?
Dr Brooke. The technical details of the operation were at the
discretion of the operating surgeon, and approximately 55% of
patients had a patch repair. There was no difference between the
percent of patients taking statin vs no statin who underwent a patch
repair.
To answer the second part of your question, I believe you were
asking in regard to statin therapy for carotid stenting?
Dr Chang. Besides putting a statin therapy on a patient with
carotid endarterectomy or stent procedure, how about putting
statin therapy on a population with a mild to moderate degree of
asymptomatic stenosis? By putting statins in that population with a
mild to moderate degree of disease, one can concentrate that statin
therapy may slow the progression of disease or even regress the
plaque. That’s my question.
Dr Brooke. Certainly I think that statin therapy would be
important for patients in the early stages of vascular disease. It
clearly should be part of the overall approach to risk factor modi-
fication in the vascular patient population. In medically managed
patients, for example, it has been shown that statin therapy can
reduce the incidence of primary stroke rates significantly. So I think
prophylactic statin therapy may theoretically prevent some patients
from ultimately going to surgery. That’s what some of the large
randomized trials have already demonstrated. But what’s less
known is what statin therapy will do for a surgical patient during
the perioperative period and how statins are working during the
perioperative period, and that was the purpose of this study.
Dr Richard Cambria (Boston, Mass). Aside from the cardiac
literature, which has shown statins to decrease the incidence of
recurrent infarction and prolong life, it seems like you can’t pick up
a journal or go to a meeting these days without finding some new
wonderful effect. The group from the Brigham has told us that it
decreases leg vein graft stenosis. Last year at this meeting, Dr
LaMuraglia of our group showed that they clearly decreased recur-
rent carotid stenosis and increased survival. So I wonder if we
won’t soon be having a sign in our offices that says you must be on
this drug.
At any rate, I have two questions about your data. The first is
that the important difference in your groups was the symptomatic
status. So was the symptomatic status of the carotid entered into
your multivariate model?
And the second is, with the higher incidence of stroke in the
combined carotid and CABG patients, would the effect still hold if
they were subtracted out?
Dr Brooke. To answer your first question, yes, patients who
were symptomatic at the time of presentation were included in our
multivariate analysis. Statin therapy was still found to be indepen-
dently associated with the reduction in stroke and mortality, ad-
justing for that symptomatic status. But it was interesting to find
that patients who were on statins presented less frequently with
strokes.
To answer your second question, the decrease in stroke and
mortality was still significantly lower when combined CABG/CEA
patients were subtracted out.
Dr Phillip Puckridge (Hamilton, New Zealand). First, we
know that statins are effective in stabilizing plaques; did you see a
bigger difference in stroke rates between the symptomatic and the
asymptomatic patients because of the effect of statins?
Second, the literature suggests that you have to be compliant
with statin therapy for a long time before you get the reduction in
stroke risk. Did you look at the timing of the patients who were on
statins before they came to surgery and whether that made a
difference?
Dr Brooke. To answer your first question, we looked at
symptomatic status in the multivariate analysis and found that the
benefit of statins was independent of the symptomatic status.
To answer your second question, one of the limitations of the
study was not knowing exactly how long patients have been on
the statin medication before their operation occurred. In med-
ical patients, there have been several studies that have shown
that patients need to be on statins for a longer period of time.
Some people have said at least 3 months before you’d see an effect,
at least in terms of lipid lowering. In terms of the pleiotropic or
lipid-independent effects of statins, it’s a little bit unclear, but this
is certainly one of the issues that would need to be addressed in
further studies.
Dr J. Fernandes (Lisbon, Portugal). We know statins stabilize
carotid plaques, and I wonder if you could tell us if there was any
difference in the echographic characteristics of the carotid plaques
in those patients with statins and without statins and if there was
any difference in the percentage of echolucent plaques in these two
groups.
My second question would be related to the long-term effects
of statins on the incidence of cardiovascular events. Please elabo-
rate on this regarding your group of patients. Was there any
difference in the incidence of cardiovascular events in those two
groups of patients—the long-term results?
Dr Brooke. To answer your first question, we did look at the
percentage of plaques that were assessed radiographically to be
ulcerative plaques, and there was no significant difference between
groups. Approximately 10% of plaques were assessed to be ulcer-
ative.
In terms of your second question, you raise an excellent
consideration. Unfortunately, our study examined only the peri-
operative impact of statin use, and we do not have the long-term
follow-up of these patients.
Dr Michael Judd (Spokane, Washington). Was antiplatelet
therapy employed equally in both cohorts of your patients?
Dr Brooke. Yes, it was.
Dr Judd. Can you elaborate on the type of therapy used? Did
you use aspirin or Plavix?
Dr Brooke. Again, patient management was surgeon specific.
However, the vast majority of the patients were treated with
dextran postoperatively for 24 hours, and almost all patients were
continued on aspirin postoperatively. Moreover, there was not a
significant difference between the statin vs no-statin cohorts in
terms of the percentage of patients taking antiplatelet medication
preoperatively.
INVITED COMMENTARY
Thomas S. Huber, MD, PhD, Gainesville, Fla
McGirt et al have reviewed their collective experience with
more than 1500 carotid endarterectomies spanning 11 years and
have reported that the use of 3-hydroxy-3-methylglutaryl coen-
zyme A reductase inhibitors (commonly referred to as statins)
independently reduced the incidence of perioperative death and
stroke. Despite the limitations of their nonrandomized, retrospec-
tive study, the results are fairly compelling and provide further
justification for the use of the statin agents. In other studies, the
statin agents have been shown to reduce perioperative mortality
after coronary artery bypass grafting, percutaneous coronary revas-
cularization, and noncardiac vascular surgery. Furthermore, they
have been shown to reduce the incidence of cerebrovascular events
in high-risk patients, reduce the progression of carotid atheroscle-
rosis, and improve graft patency after infrainguinal bypass. The
mechanisms responsible for these beneficial effects are likely mul-
tifactorial and include plaque stabilization and attenuation of
inflammatory mediators, in addition to the reduction of the serum
lipid levels. Although their use in many of these clinical settings
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